Drug Trial Radar · NCT05734482
Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Feb 15, 2023
Primary completion
Jul 3, 2023
Study completion Jul 3, 2023
Sponsor
- Lead sponsor
- Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blinded, controlled Phase I study of CMAB015 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of CMAB015 versus Cosentyx(Secukinumab ) in healthy male subjects after a single dose.
Conditions
- Psoriasis
Interventions
SecukinumabBiological
for subcutaneous injection only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite timeTime frame: up to 2688 hours
- Maximum Concentration of SecukinumabTime frame: up to 2688 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.